Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.

RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections.

Motsch J, Murta de Oliveira C, Stus V, Köksal I, Lyulko O, Boucher HW, Kaye KS, File TM, Brown ML, Khan I, Du J, Joeng HK, Tipping RW, Aggrey A, Young K, Kartsonis NA, Butterton JR, Paschke A.

Clin Infect Dis. 2019 Aug 10. pii: ciz530. doi: 10.1093/cid/ciz530. [Epub ahead of print]

PMID:
31400759
2.

A Mortality Analysis of Letermovir Prophylaxis for Cytomegalovirus (CMV) in CMV-Seropositive Recipients of Allogeneic Hematopoietic-Cell Transplantation.

Ljungman P, Schmitt M, Marty FM, Maertens J, Chemaly RF, Kartsonis NA, Butterton JR, Wan H, Teal VL, Sarratt K, Murata Y, Leavitt RY, Badshah C.

Clin Infect Dis. 2019 Jun 8. pii: ciz490. doi: 10.1093/cid/ciz490. [Epub ahead of print]

PMID:
31179485
3.

Assessment of Drug Interaction Potential Between the Hepatitis C Virus Direct-Acting Antiviral Agents Elbasvir/Grazoprevir and the Nucleotide Analog Reverse-Transcriptase Inhibitor Tenofovir Disoproxil Fumarate.

Feng HP, Guo Z, Caro L, Talaty JE, Mangin E, Panebianco D, Fandozzi C, Zhu Y, Marshall W, Huang X, Hanley WD, Jumes P, Valesky R, Martinho M, Butterton JR, Iwamoto M, Yeh WW.

Clin Pharmacol Drug Dev. 2019 Jun 7. doi: 10.1002/cpdd.701. [Epub ahead of print]

PMID:
31173674
4.

Pharmacokinetic Interactions between the Hepatitis C Virus Inhibitors Elbasvir and Grazoprevir and HIV Protease Inhibitors Ritonavir, Atazanavir, Lopinavir, and Darunavir in Healthy Volunteers.

Feng HP, Caro L, Fandozzi C, Chu X, Guo Z, Talaty J, Panebianco D, Dunnington K, Du L, Hanley WD, Fraser IP, Mitselos A, Denef JF, De Lepeleire I, de Hoon JN, Vandermeulen C, Marshall WL, Jumes P, Huang X, Martinho M, Valesky R, Butterton JR, Iwamoto M, Yeh WW.

Antimicrob Agents Chemother. 2019 Mar 27;63(4). pii: e02142-18. doi: 10.1128/AAC.02142-18. Print 2019 Apr.

PMID:
30745392
5.

Pharmacokinetics of elbasvir and grazoprevir in subjects with end-stage renal disease or severe renal impairment.

Caro L, Wenning L, Feng HP, Guo Z, Du L, Bhagunde P, Fandozzi C, Panebianco D, Marshall WL, Butterton JR, Iwamoto M, Yeh WW.

Eur J Clin Pharmacol. 2019 May;75(5):665-675. doi: 10.1007/s00228-018-2585-3. Epub 2019 Jan 25.

PMID:
30680407
6.

Assessment of drug interaction potential between the HCV direct-acting antiviral agents elbasvir/grazoprevir and the HIV integrase inhibitors raltegravir and dolutegravir.

Feng HP, Guo Z, Ross LL, Fraser I, Panebianco D, Jumes P, Fandozzi C, Caro L, Talaty J, Ma J, Mangin E, Huang X, Marshall WL, Butterton JR, Iwamoto M, Yeh WW.

J Antimicrob Chemother. 2019 Mar 1;74(3):710-717. doi: 10.1093/jac/dky465.

PMID:
30541077
7.

Erratum for Rhee et al., "Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Relebactam, a β-Lactamase Inhibitor, in Combination with Imipenem and Cilastatin in Healthy Participants".

Rhee EG, Rizk ML, Calder N, Nefliu M, Warrington SJ, Schwartz MS, Mangin E, Boundy K, Bhagunde P, Colon-Gonzalez F, Jumes P, Liu Y, Butterton JR.

Antimicrob Agents Chemother. 2018 Nov 26;62(12). pii: e02197-18. doi: 10.1128/AAC.02197-18. Print 2018 Dec. No abstract available.

8.

No Pharmacokinetic Interactions Between Elbasvir or Grazoprevir and Methadone in Participants Receiving Maintenance Opioid Agonist Therapy.

Feng HP, Guo Z, Caro L, Marshall WL, Liu F, Panebianco D, Vaddady P, Reitmann C, Jumes P, Wolford D, Fraser I, Valesky R, Martinho M, Butterton JR, Iwamoto M, Webster L, Yeh WW.

Clin Transl Sci. 2018 Nov;11(6):553-561. doi: 10.1111/cts.12564. Epub 2018 Jul 24.

9.

No Pharmacokinetic Interactions Between Elbasvir or Grazoprevir and Buprenorphine/Naloxone in Healthy Participants and Participants Receiving Stable Opioid Agonist Therapy.

Feng HP, Guo Z, Caro L, Marshall WL, Liu F, Panebianco D, Vaddady P, Barbour A, Reitmann C, Jumes P, Gilmartin J, Wolford D, Valesky R, Martinho M, Butterton JR, Iwamoto M, Fraser I, Webster L, Yeh WW.

Clin Transl Sci. 2018 Nov;11(6):562-572. doi: 10.1111/cts.12565. Epub 2018 Jul 24.

10.

Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Relebactam, a β-Lactamase Inhibitor, in Combination with Imipenem and Cilastatin in Healthy Participants.

Rhee EG, Rizk ML, Calder N, Nefliu M, Warrington SJ, Schwartz MS, Mangin E, Boundy K, Bhagunde P, Colon-Gonzalez F, Jumes P, Liu Y, Butterton JR.

Antimicrob Agents Chemother. 2018 Aug 27;62(9). pii: e00280-18. doi: 10.1128/AAC.00280-18. Print 2018 Sep. Erratum in: Antimicrob Agents Chemother. 2018 Nov 26;62(12):.

11.

Antiviral Activity, Safety, and Tolerability of Multiple Ascending Doses of Elbasvir or Grazoprevir in Participants Infected With Hepatitis C Virus Genotype-1 or -3.

Yeh WW, Fraser IP, Jumes P, Petry A, Lepeleire I, Robberechts M, Reitmann C, Van Dyck K, Huang X, Guo Z, Panebianco D, Nachbar RB, O'Mara E, Wagner JA, Butterton JR, Dutko FJ, Moiseev V, Kobalava Z, Hüser A, Visan S, Schwabe C, Gane E, Popa S, Ghicavii N, Uhle M, Wagner F.

Clin Ther. 2018 May;40(5):704-718.e6. doi: 10.1016/j.clinthera.2018.03.002. Epub 2018 Apr 25.

PMID:
29703432
12.

Pharmacokinetics and Tolerability of Letermovir Coadministered With Azole Antifungals (Posaconazole or Voriconazole) in Healthy Subjects.

Marshall WL, McCrea JB, Macha S, Menzel K, Liu F, van Schanke A, de Haes JIU, Hussaini A, Jordan HR, Drexel M, Kantesaria BS, Tsai C, Cho CR, Hulskotte EGJ, Butterton JR, Iwamoto M.

J Clin Pharmacol. 2018 Jul;58(7):897-904. doi: 10.1002/jcph.1094. Epub 2018 Mar 26.

PMID:
29578577
13.

Characterisation of the absorption, distribution, metabolism, excretion and mass balance of doravirine, a non-nucleoside reverse transcriptase inhibitor in humans.

Sanchez RI, Fillgrove KL, Yee KL, Liang Y, Lu B, Tatavarti A, Liu R, Anderson MS, Behm MO, Fan L, Li Y, Butterton JR, Iwamoto M, Khalilieh SG.

Xenobiotica. 2019 Apr;49(4):422-432. doi: 10.1080/00498254.2018.1451667. Epub 2018 Mar 28.

PMID:
29557716
14.

Pharmacokinetic Interactions Between Elbasvir/Grazoprevir and Immunosuppressant Drugs in Healthy Volunteers.

Feng HP, Caro L, Fandozzi CM, Guo Z, Talaty J, Wolford D, Panebianco D, Iwamoto M, Butterton JR, Yeh WW.

J Clin Pharmacol. 2018 May;58(5):666-673. doi: 10.1002/jcph.1052. Epub 2018 Jan 12.

PMID:
29329497
15.

Intrapulmonary Pharmacokinetics of Relebactam, a Novel β-Lactamase Inhibitor, Dosed in Combination with Imipenem-Cilastatin in Healthy Subjects.

Rizk ML, Rhee EG, Jumes PA, Gotfried MH, Zhao T, Mangin E, Bi S, Chavez-Eng CM, Zhang Z, Butterton JR.

Antimicrob Agents Chemother. 2018 Feb 23;62(3). pii: e01411-17. doi: 10.1128/AAC.01411-17. Print 2018 Mar.

16.

Pharmacokinetics, Safety, and Tolerability of Single-Dose Elbasvir in Participants with Hepatic Impairment.

Marshall WL, Feng HP, Wenning L, Garrett G, Huang X, Liu F, Panebianco D, Caro L, Fandozzi C, Lasseter KC, Preston RA, Marbury T, Butterton JR, Iwamoto M, Yeh WW.

Eur J Drug Metab Pharmacokinet. 2018 Jun;43(3):321-329. doi: 10.1007/s13318-017-0451-9.

PMID:
29247332
17.

Effect of Hepatic Impairment on the Pharmacokinetics of Grazoprevir, a Hepatitis C Virus Protease Inhibitor.

Caro L, Wenning L, Guo Z, Fraser IP, Fandozzi C, Talaty J, Panebianco D, Ho M, Uemura N, Reitmann C, Angus P, Gane E, Marbury T, Smith WB, Iwamoto M, Butterton JR, Yeh WW.

Antimicrob Agents Chemother. 2017 Nov 22;61(12). pii: e00813-17. doi: 10.1128/AAC.00813-17. Print 2017 Dec.

18.

Safety and efficacy of an 8-week regimen of grazoprevir plus ruzasvir plus uprifosbuvir compared with grazoprevir plus elbasvir plus uprifosbuvir in participants without cirrhosis infected with hepatitis C virus genotypes 1, 2, or 3 (C-CREST-1 and C-CREST-2, part A): two randomised, phase 2, open-label trials.

Gane EJ, Pianko S, Roberts SK, Thompson AJ, Zeuzem S, Zuckerman E, Ben-Ari Z, Foster GR, Agarwal K, Laursen AL, Gerstoft J, Gao W, Huang HC, Fitzgerald B, Fernsler D, Li JJ, Grandhi A, Liu H, Su FH, Wan S, Zeng Z, Chen HL, Dutko FJ, Nguyen BT, Wahl J, Robertson MN, Barr E, Yeh WW, Plank RM, Butterton JR, Esteban R.

Lancet Gastroenterol Hepatol. 2017 Nov;2(11):805-813. doi: 10.1016/S2468-1253(17)30159-0. Epub 2017 Aug 10.

PMID:
28802816
19.

Safety and efficacy of a fixed-dose combination regimen of grazoprevir, ruzasvir, and uprifosbuvir with or without ribavirin in participants with and without cirrhosis with chronic hepatitis C virus genotype 1, 2, or 3 infection (C-CREST-1 and C-CREST-2, part B): two randomised, phase 2, open-label trials.

Lawitz E, Buti M, Vierling JM, Almasio PL, Bruno S, Ruane PJ, Hassanein TI, Muellhaupt B, Pearlman B, Jancoriene L, Gao W, Huang HC, Shepherd A, Tannenbaum B, Fernsler D, Li JJ, Grandhi A, Liu H, Su FH, Wan S, Dutko FJ, Nguyen BT, Wahl J, Robertson MN, Barr E, Yeh WW, Plank RM, Butterton JR, Yoshida EM.

Lancet Gastroenterol Hepatol. 2017 Nov;2(11):814-823. doi: 10.1016/S2468-1253(17)30163-2. Epub 2017 Aug 10.

PMID:
28802814
20.

No Pharmacokinetic Interaction Between the Hepatitis C Virus Inhibitors Elbasvir/Grazoprevir and Famotidine or Pantoprazole.

Feng HP, Vaddady P, Guo Z, Liu F, Panebianco D, Levine V, Caro L, Butterton JR, Iwamoto M, Yeh WW.

Clin Transl Sci. 2017 Sep;10(5):360-365. doi: 10.1111/cts.12465. Epub 2017 Jun 17.

21.

The Effect of Single and Multiple Doses of Rifampin on the Pharmacokinetics of Doravirine in Healthy Subjects.

Yee KL, Khalilieh SG, Sanchez RI, Liu R, Anderson MS, Manthos H, Judge T, Brejda J, Butterton JR.

Clin Drug Investig. 2017 Jul;37(7):659-667. doi: 10.1007/s40261-017-0513-4.

PMID:
28353169
22.

No clinically meaningful pharmacokinetic interaction between the hepatitis C virus inhibitors elbasvir and grazoprevir and the oral contraceptives ethinyl estradiol and levonorgestrel.

Marshall WL, Feng HP, Caro L, Talaty J, Guo Z, Huang X, Panebianco D, Ma J, Mangin E, O'Reilly TE, Butterton JR, Yeh WW.

Eur J Clin Pharmacol. 2017 May;73(5):593-600. doi: 10.1007/s00228-017-2216-4. Epub 2017 Feb 24.

PMID:
28233047
23.

Erratum to: A Two-Way Steady-State Pharmacokinetic Interaction Study of Doravirine (MK-1439) and Dolutegravir.

Anderson MS, Khalilieh S, Yee KL, Liu R, Fan L, Rizk ML, Shah V, Hussaini A, Song I, Ross LL, Butterton JR.

Clin Pharmacokinet. 2017 Jun;56(6):679-681. doi: 10.1007/s40262-017-0517-5. No abstract available.

PMID:
28185217
24.

A Two-Way Steady-State Pharmacokinetic Interaction Study of Doravirine (MK-1439) and Dolutegravir.

Anderson MS, Khalilieh S, Yee KL, Liu R, Fan L, Rizk ML, Shah V, Hussaini A, Song I, Ross LL, Butterton JR.

Clin Pharmacokinet. 2017 Jun;56(6):661-669. doi: 10.1007/s40262-016-0458-4. Erratum in: Clin Pharmacokinet. 2017 Jun;56(6):679-681.

PMID:
27699622
25.

A randomized, double-blind, placebo-controlled, short-term monotherapy study of doravirine in treatment-naive HIV-infected individuals.

Schürmann D, Sobotha C, Gilmartin J, Robberechts M, De Lepeleire I, Yee KL, Guo Y, Liu R, Wagner F, Wagner JA, Butterton JR, Anderson MS.

AIDS. 2016 Jan 2;30(1):57-63. doi: 10.1097/QAD.0000000000000876.

PMID:
26372481
26.

Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized Trial.

Zeuzem S, Ghalib R, Reddy KR, Pockros PJ, Ben Ari Z, Zhao Y, Brown DD, Wan S, DiNubile MJ, Nguyen BY, Robertson MN, Wahl J, Barr E, Butterton JR.

Ann Intern Med. 2015 Jul 7;163(1):1-13. doi: 10.7326/M15-0785.

PMID:
25909356
27.

Clinical pharmacology profile of boceprevir, a hepatitis C virus NS3 protease inhibitor: focus on drug-drug interactions.

Khalilieh S, Feng HP, Hulskotte EG, Wenning LA, Butterton JR.

Clin Pharmacokinet. 2015 Jun;54(6):599-614. doi: 10.1007/s40262-015-0260-8. Review.

PMID:
25787025
28.

Pharmacokinetic interaction between HCV protease inhibitor boceprevir and methadone or buprenorphine in subjects on stable maintenance therapy.

Hulskotte EG, Bruce RD, Feng HP, Webster LR, Xuan F, Lin WH, O'Mara E, Wagner JA, Butterton JR.

Eur J Clin Pharmacol. 2015 Mar;71(3):303-11. doi: 10.1007/s00228-014-1789-4. Epub 2015 Feb 11.

PMID:
25666027
29.

Safety, tolerability and pharmacokinetics of doravirine, a novel HIV non-nucleoside reverse transcriptase inhibitor, after single and multiple doses in healthy subjects.

Anderson MS, Gilmartin J, Cilissen C, De Lepeleire I, Van Bortel L, Dockendorf MF, Tetteh E, Ancona JK, Liu R, Guo Y, Wagner JA, Butterton JR.

Antivir Ther. 2015;20(4):397-405. doi: 10.3851/IMP2920. Epub 2014 Dec 3.

PMID:
25470746
30.

Pharmacokinetic and pharmacodynamic interactions between the hepatitis C virus protease inhibitor, boceprevir, and the oral contraceptive ethinyl estradiol/norethindrone.

Lin WH, Feng HP, Shadle CR, O'Reilly T, Wagner JA, Butterton JR.

Eur J Clin Pharmacol. 2014 Sep;70(9):1107-13. doi: 10.1007/s00228-014-1711-0. Epub 2014 Jul 5.

PMID:
24992979
31.

Pharmacokinetic evaluation of the interaction between hepatitis C virus protease inhibitor boceprevir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and pravastatin.

Hulskotte EG, Feng HP, Xuan F, Gupta S, van Zutven MG, O'Mara E, Wagner JA, Butterton JR.

Antimicrob Agents Chemother. 2013 Jun;57(6):2582-8. doi: 10.1128/AAC.02347-12. Epub 2013 Mar 25.

32.

Pharmacokinetic interactions between the hepatitis C virus protease inhibitor boceprevir and ritonavir-boosted HIV-1 protease inhibitors atazanavir, darunavir, and lopinavir.

Hulskotte EG, Feng HP, Xuan F, van Zutven MG, Treitel MA, Hughes EA, O'Mara E, Youngberg SP, Wagner JA, Butterton JR.

Clin Infect Dis. 2013 Mar;56(5):718-26. doi: 10.1093/cid/cis968. Epub 2012 Nov 15.

PMID:
23155151
33.

A novel murine infection model for Shiga toxin-producing Escherichia coli.

Mallick EM, McBee ME, Vanguri VK, Melton-Celsa AR, Schlieper K, Karalius BJ, O'Brien AD, Butterton JR, Leong JM, Schauer DB.

J Clin Invest. 2012 Nov;122(11):4012-24. doi: 10.1172/JCI62746. Epub 2012 Oct 8.

34.

Case records of the Massachusetts General Hospital. Case 14-2007. A 59-year-old man with fever and pain and swelling of both eyes and the right ear.

Butterton JR, Collier DS, Romero JM, Zembowicz A.

N Engl J Med. 2007 May 10;356(19):1980-8. No abstract available.

PMID:
17494931
35.

Case records of the Massachusetts General Hospital. Case 8-2007. A 48-year-old man with chest pain followed by cardiac arrest.

Lewis GD, Holmes CB, Holmvang G, Butterton JR.

N Engl J Med. 2007 Mar 15;356(11):1153-62. No abstract available. Erratum in: N Engl J Med. 2007 Jul 19;357(3):313. Dosage error in article text.

PMID:
17360994
36.

A targeted intervention for the career development of women in academic medicine.

Jagsi R, Butterton JR, Starr R, Tarbell NJ.

Arch Intern Med. 2007 Feb 26;167(4):343-5. No abstract available.

PMID:
17325295
37.

Fabry disease in mice protects against lethal disease caused by Shiga toxin-expressing enterohemorrhagic Escherichia coli.

Cilmi SA, Karalius BJ, Choy W, Smith RN, Butterton JR.

J Infect Dis. 2006 Oct 15;194(8):1135-40. Epub 2006 Sep 8.

PMID:
16991089
38.

Renal injury is a consistent finding in Dutch Belted rabbits experimentally infected with enterohemorrhagic Escherichia coli.

Garcia A, Bosques CJ, Wishnok JS, Feng Y, Karalius BJ, Butterton JR, Schauer DB, Rogers AB, Fox JG.

J Infect Dis. 2006 Apr 15;193(8):1125-34. Epub 2006 Mar 6.

PMID:
16544253
39.

Delivery of heterologous protein antigens via hemolysin or autotransporter systems by an attenuated ler mutant of rabbit enteropathogenic Escherichia coli.

Zhu C, Ruiz-Perez F, Yang Z, Mao Y, Hackethal VL, Greco KM, Choy W, Davis K, Butterton JR, Boedeker EC.

Vaccine. 2006 May 1;24(18):3821-31. Epub 2005 Jul 25.

PMID:
16098637
40.

Variation in the Shiga toxin region of 20th-century epidemic and endemic Shigella dysenteriae 1 strains.

Greco KM, McDonough MA, Butterton JR.

J Infect Dis. 2004 Jul 15;190(2):330-4. Epub 2004 Jun 9.

PMID:
15216469
41.

Vibrio cholerae VibF is required for vibriobactin synthesis and is a member of the family of nonribosomal peptide synthetases.

Butterton JR, Choi MH, Watnick PI, Carroll PA, Calderwood SB.

J Bacteriol. 2000 Mar;182(6):1731-8.

42.
43.

In vivo expression and immunoadjuvancy of a mutant of heat-labile enterotoxin of Escherichia coli in vaccine and vector strains of Vibrio cholerae.

Ryan ET, Crean TI, John M, Butterton JR, Clements JD, Calderwood SB.

Infect Immun. 1999 Apr;67(4):1694-701.

44.
46.

Protective immunity against Clostridium difficile toxin A induced by oral immunization with a live, attenuated Vibrio cholerae vector strain.

Ryan ET, Butterton JR, Smith RN, Carroll PA, Crean TI, Calderwood SB.

Infect Immun. 1997 Jul;65(7):2941-9.

47.
48.

Development of a germfree mouse model of Vibrio cholerae infection.

Butterton JR, Ryan ET, Shahin RA, Calderwood SB.

Infect Immun. 1996 Oct;64(10):4373-7.

49.

Heterologous antigen expression in Vibrio cholerae vector strains.

Butterton JR, Beattie DT, Gardel CL, Carroll PA, Hyman T, Killeen KP, Mekalanos JJ, Calderwood SB.

Infect Immun. 1995 Jul;63(7):2689-96.

50.

Supplemental Content

Loading ...
Support Center